Mizuno Y, et al. - Here, the authors performed a randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson's disease (PD). They concluded that selegiline monotherapy decreased the total Unified Parkinson Disease Rating Scale part I + II + III score. It was well tolerated in Japanese patients with early PD.